Myrlosar (Losartan Potassium)

Losartan potassium, the active ingredient in Myrlosar, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and related cardiovascular conditions in adult patients. By selectively antagonizing angiotensin II type 1 receptors, the drug relaxes blood vessels, lowers systemic vascular resistance, and helps prevent complications such as stroke and heart failure.

GNH USA supplies Myrlosar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Losartan potassium is used to treat conditions related to the renin‑angiotensin system and cardiovascular disease. - Hypertension: lowers blood pressure and reduces risk of cardiovascular events. - Heart failure: improves symptoms and decreases hospitalization rates in patients with reduced ejection fraction. - Diabetic nephropathy: slows progression of kidney disease in patients with type 2 diabetes. - Stroke risk reduction: helps lower the likelihood of stroke in patients with hypertension and additional risk factors.

Losartan potassium may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling unusually tired. - Upper respiratory infection: nasopharyngitis or mild cough. - Hyperkalemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hepatic injury: abnormal liver enzyme elevations. - Neutropenia: low white‑blood‑cell count.

When prescribing Myrlosar, clinicians should consider several safety measures. - Monitor blood pressure: check regularly to ensure therapeutic effect. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium levels. - Avoid in patients with known hypersensitivity to ARBs. - Pregnancy: contraindicated in second and third trimester due to fetal risk. - Store at room temperature: keep in original container, protect from moisture and light.

Losartan potassium can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Dual blockade with ACE inhibitors or other ARBs: higher incidence of hypotension and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - NSAIDs (high‑dose or chronic): can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, risking toxicity. - Cyclosporine or tacrolimus: can elevate serum creatinine. - Rifampin: may reduce losartan plasma concentrations. - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment.